From the Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710
Received for publication, December 5, 2000, and in revised form, January 11, 2001
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Dimethyl sulfoxide reductase (DMSOR),
trimethylamine-N-oxide reductase (TMAOR), and biotin
sulfoxide reductase (BSOR) are members of a class of bacterial
oxotransferases that contain the bis(molybdopterin guanine
dinucleotide)molybdenum cofactor. The presence of a Tyr residue in the
active site of DMSOR and BSOR that is missing in TMAOR has been
implicated in the inability of TMAOR, unlike DMSOR and BSOR, to utilize
S-oxides. To test this hypothesis, Escherichia
coli TMAOR was cloned and expressed at high levels, and
site-directed mutagenesis was utilized to generate the Tyr-114
Rhodobacter sphaeroides and Rhodobacter
capsulatus dimethyl sulfoxide reductase
(DMSOR),1 Escherichia
coli and Shewanella massilia
trimethylamine-N-oxide reductase (TMAOR), and R. sphaeroides biotin sulfoxide reductase (BSOR) are members of a
class of bacterial oxotransferases that all contain the
bis(molybdopterin guanine dinucleotide) form of the molybdenum cofactor
(bis(MGD)Mo) seen in Fig. 1 (1-4). These enzymes are ideal targets for spectroscopic and kinetic studies of the
molybdenum center since they do not contain additional cofactors. In
contrast, in all other molybdoproteins studied to date, the low energy
absorption bands of the molybdenum atom are overshadowed by prosthetic
groups such as hemes, iron-sulfur centers, and flavins. Mechanistic
studies are aided by the extensive structural information reported for
this family, including several x-ray crystal structures (2, 4-8),
analysis by extended x-ray absorption fine structure spectroscopy
(EXAFS) (9-11), EPR (10-14), and resonance Raman spectroscopy (15,
16).
Ala and Phe variants of Rhodobacter sphaeroides DMSOR
and insert a Tyr residue into the equivalent position in TMAOR.
Although all of the mutants turn over in a manner similar to their
respective wild-type enzymes, mutation of Tyr-114 in DMSOR results in a
decreased specificity for S-oxides and an increased specificity for trimethylamine-N-oxide (Me3NO),
with a greater change observed for DMSOR-Y114A. Insertion of a Tyr into
TMAOR results in a decreased preference for Me3NO relative
to dimethyl sulfoxide. Kinetic analysis and UV-visible absorption
spectra indicate that the ability of DMSOR to be reduced by dimethyl
sulfide is lost upon mutation of Tyr-114 and that TMAOR does not
exhibit this activity even in the Tyr insertion mutant.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
View larger version (10K):
[in a new window]
Fig. 1.
Bis(molybdopterin guanine dinucleotide)
molybdenum cofactor.
Resonance Raman studies on BSOR and DMSOR indicate that both enzymes
function by an oxo transfer mechanism whereby the oxo group from the
substrate is directly transferred to the molybdenum atom (Fig.
2) (15, 16). This process is reversible
in DMSOR, and the ability of this enzyme to be reduced by dimethyl
sulfide (Me2S) has been extensively studied (7, 11, 15,
17). However, resonance Raman analysis has indicated that BSOR is
unable to be reduced with either Me2S or by biotin (16).
Other than mutation of the protein ligands to the molybdenum in DMSOR
and BSOR (18, 19), no mutagenic studies have been reported for TMAOR,
BSOR, or Rhodobacter DMSOR, and there is little information about the roles of other amino acids in enzymatic activity.
|
Alignment of R. sphaeroides and R. capsulatus DMSOR to E. coli and S. massilia TMAOR and R. sphaeroides BSOR indicates 22% sequence identity and 48% sequence similarity between all five enzymes. Despite this similarity, there are striking differences in their physiological roles, electron donors, and substrate specificity. TMAOR functions as the final enzyme in the anaerobic electron transport pathway that utilizes Me3NO as the terminal electron acceptor (20). Although DMSOR also functions as a terminal enzyme during anaerobic respiration, it is able to utilize a greater variety of substrates including Me3NO and dimethyl sulfoxide (Me2SO) (21). BSOR, a cytoplasmic protein whose possible roles include scavenging biotin sulfoxide (BSO) to generate biotin and protecting the cell from oxidative damage (22), has also been shown to use a variety of S- and N-oxides (23).
The x-ray crystallographic structure of DMSOR has generated great
interest in the role of the Tyr at position 114 during catalytic turnover of the enzyme. In the 1.3-Å crystal structure of R. sphaeroides DMSOR, the bis(MGD)Mo active site exhibits two
different coordination geometries (5). In the catalytically active,
hexa-coordinated molybdenum site, the single oxo group is coordinated
by Trp-116 (Fig. 3B), whereas
in the inactive, penta-coordinated molybdenum environment, Tyr-114 is
hydrogen-bonded to one of two oxo groups (Fig. 3C). Although
sequence alignments have shown that BSOR contains a residue equivalent
to Tyr-114, this residue is missing in E. coli and S. massilia TMAOR (Fig. 3, A and D). Since both
BSOR and DMSOR are able to reduce a wide variety of S- and
N-oxides whereas TMAOR shows a more limited specificity for
N-oxides (24), Tyr-114 has been postulated to be responsible
for this variance in substrate specificity (4, 25).
|
Although R. sphaeroides DMSOR and BSOR were previously
cloned and heterologously expressed in E. coli (3, 23, 26), TMAOR has not been cloned previously. In the studies reported here,
E. coli TMAOR has been cloned and the recombinant protein purified, setting the stage for a comprehensive study of the role of
Tyr-114 in this family of enzymes. This residue has been mutated to
both Ala and Phe in DMSOR, and a Tyr has been inserted into TMAOR in an
equivalent position. The molybdenum coordination environment of the
wild-type and mutant proteins has been probed using UV-visible absorption spectroscopy. The activities of both wild-type and mutant
proteins have been analyzed by steady-state kinetics with both S- and N-oxides in the forward direction,
and the efficiency of Me2S reduction of these enzymes has
been measured. The presence of these mutations does not appear to
affect stability or cofactor incorporation. The mutation of Tyr-114 in
DMSOR does increase the specificity for N-oxides while
decreasing the specificity for S-oxides, and insertion of
the Tyr residue in TMAOR increases the specificity for
S-oxides with a concomitant decrease in specificity for
N-oxides. Mutation of Tyr-114 in DMSOR also results in
inefficient reduction of the enzyme by Me2S.
![]() |
EXPERIMENTAL PROCEDURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cloning of E. coli TMAOR--
The first 117 nucleotides of the
E. coli torA sequence encode a 39-amino acid N-terminal
signal sequence that targets TMAOR to the periplasm and is cleaved to
form the mature enzyme (27). The structural gene for TMAOR without the
periplasmic signal sequence was isolated from DH5 genomic DNA using
PCR primers created from the E. coli K12 torA
gene sequence (GenBankTM accession number X73888). One
primer inserted an NdeI site and a new start codon
immediately 5' to the codon for the first amino acid of the mature
protein, and the second created a HindIII site 36 nucleotides downstream from the stop codon. The resulting DNA segment
containing the torA sequence was ligated directly into the
pCR2.1 cloning vector using the Topo TA cloning kit (Invitrogen). The
consensus sequence of three independent clones confirmed the previously
published K12 sequence (27). Primers were obtained from Life
Technologies, Inc., and automated sequencing was accomplished by the
Duke University DNA Analysis Facility.
Creation of TMAOR Expression Construct-- One plasmid clone containing a single polymerase error that changed Trp-576 to Ala was selected for further manipulations. Due to difficulties in growing cells containing the pCR2.1 cloning vector during mutagenesis, the TMAOR coding sequence was released with HindIII and transferred into the pBluescript II Ks(+) cloning vector (Stratagene). The polymerase error was repaired by site-directed mutagenesis on double-stranded DNA using the CLONTECH Transformer Site-directed Mutagenesis Kit to obtain pKJ125. This plasmid was digested with NdeI and HindIII, and the coding sequence was ligated into the pET-29a(+) expression vector (Novagen) to form pKJ525 (Table I) which encodes for mature TMAOR. To aid in purification of the protein, the TMAOR coding region of pKJ125 was released with HindIII and NdeI and ligated into pET-28a(+) (Novagen) to create pKJ725, which encodes an N-terminal His6-tagged version of TMAOR. The coding sequence containing the structural gene, and the N-terminal His tag from pKJ725 was excised using HindIII and NcoI and ligated into the pTrc 99 A expression vector (Amersham Pharmacia Biotech) to form pKJ825.
|
Site-directed mutagenesis was used to insert a Tyr residue between amino acids 119 and 120 of the TMAOR coding sequence in pKJ725. The sequence for the structural gene and the N-terminal His tag was excised using HindIII and NcoI and ligated into pTrc 99 A to form pKJ830. This plasmid expresses the TMAOR+Y variant of TMAOR, which contains a Tyr residue in a location equivalent to Tyr-114 in DMSOR.
Creation of DMSOR Constructs-- Site-directed mutagenesis was performed on pJH118 (18) to change the Tyr at position 144 to either Ala or Phe. The mutated coding sequences were subsequently liberated using HindIII and NdeI and ligated into pET-28a(+) in frame with the N-terminal His6 tag to produce pJN711 and pJN712, the expression vectors for DMSOR-Y114A and DMSOR-Y114F, respectively.
Expression--
All of the pTrc 99 A-based expression
vectors (pJH820 (28), pKJ825, and pKJ830) were transformed into RK4353
E. coli cells (29). Growth and expression in these cells
were done as described previously (3) with the exception that
isopropyl--D-thiogalactopyranoside (IPTG) was present at
10 µM.
The RK4353 strain was DE3-lysogenized using the DE3 lysogenization
kit from Novagen to create the RK4353(DE3) strain. All of the pET-based
expression plasmids (pJH720, pKJ725, pKJ525, pJN711, and pJN712) were
transformed into these cells. The resulting strains were subsequently
transformed a second time with pLysS (Novagen). Conditions for growth
and expression were as described previously (3), with the exception
that 30 µg/ml chloramphenicol and 34 µg/ml kanamycin were used as
the sole antibiotics, and expression was induced with 40 µM IPTG.
Purification of TMAOR-- Cells expressing TMAOR were harvested by centrifugation at 5,000 × g and resuspended in 50 mM sodium phosphate buffer, pH 8.0, containing 300 mM NaCl (PN buffer). Cell lysis was achieved by three passages through the 112-µm interaction chamber of a Microfluidics M110L Microfluidizer Processor at 16,000-18,000 pounds/square inch. The resulting extract was stirred at room temperature for 20 min with ~10 µg/ml DNase I and then centrifuged at 11,000 × g for 25 min at 4 °C. The supernatant was adjusted to pH 6.5 with HCl, heated in a boiling water bath to 65 °C, maintained at 65 °C for 1 min, cooled rapidly in an ice bath, and then centrifuged at 11,000 × g for 25 min. Imidazole was added to a final concentration of 10 mM; the pH was adjusted to 7.5 with NaOH, and the solution was centrifuged again. The supernatant was then equilibrated with 40 ml of Ni2+-NTA affinity resin (Qiagen) by gentle stirring at 4 °C for 15 min. This slurry was loaded onto a gravity flow column and subsequently washed with 2 column volumes of PN buffer at pH 7.5 containing 10 mM imidazole, 8 column volumes of the same solution at pH 8.0, and 3 column volumes of PN buffer, pH 8, containing 20 mM imidazole. TMAOR was eluted at pH 8.0 with PN buffer containing 200 mM imidazole. The fractions containing TMAOR were combined, dialyzed against 50 mM Tris, pH 7.5, and purified using a Q-Sepharose fast protein liquid chromatography column with a 23-ml bed volume. The column was washed with 1 column volume of 50 mM Tris, pH 7.5, followed by a 2-column volume 0-300 mM gradient of NaCl, and TMAOR was then eluted with a 2-column volume wash at 300 mM NaCl. The fractions containing TMAOR were combined and buffer exchanged into 50 mM Tris, pH 7.5, using either dialysis or a 100-ml Superose-12 fast protein liquid chromatography column. Q-Sepharose fast flow and Superose-12 resin were obtained from Amersham Pharmacia Biotech.
A more stable form of TMAOR was obtained by cycling the protein during purification. The clarified lysate was placed in a Coy anaerobic chamber containing a mixture of carbon dioxide, hydrogen, and nitrogen and reduced with dithionite in the presence of methyl viologen until a dark blue color was present. A 100 mM solution of Me3NO was then added in a dropwise fashion until the solution lost all blue color, and the process was repeated. The resulting solution was immediately brought to pH 6.5 for the heat step and further purification as already described. TMAOR+Y was purified in the same manner as the wild-type enzyme including the cycling step.
Purification of DMSOR-- Native DMSOR was purified from R. sphaeroides (1), and recombinant DMSOR, DMSOR-Y114A, and DMSOR-Y114F were purified from E. coli as described previously (18) with the exception that a Microfluidics M110L Microfluidizer Processor was used to break open the cells.
Protein Analysis--
The molybdenum content of the purified
proteins was analyzed using a PerkinElmer Life Sciences Zeeman 3030 atomic absorption spectrometer as described previously (18). Pure
samples of DMSOR were quantitated spectrophotometrically at 280 nm
using an extinction coefficient of 200,000 M1 cm
1
or 2.3 ml mg
1 cm
1
(1). For quantitation of TMAOR or total protein, the Pierce BCA assay
was used as described in the manufacturer's protocol, with purified
R. sphaeroides DMSOR as the standard. Guanine analysis was
performed as described previously (18).
UV-visible Absorption Spectra-- Absorption spectroscopy was carried out using a Shimadzu UV-2101 PC spectrophotometer. All spectra were recorded in 50 mM Tris-HCl, pH 7.5, and normalized to 5 mg/ml unless otherwise indicated. Dithionite-reduced spectra were recorded under anaerobic conditions as described previously (3), and re-oxidized spectra were obtained by the injection of anaerobic substrate directly into the cuvette containing the dithionite-reduced enzyme.
Me2S-reduced UV-visible Absorption Spectra-- To obtain Me2S-reduced spectra, purified recombinant DMSOR, DMSOR-Y114F, and DMSOR-Y114A were reduced under anaerobic conditions in the Coy chamber, re-oxidized with substrate, and dialyzed against 2× 1 liter of 50 mM Tris, pH 7.5. TMAOR and TMAOR+Y spectra were obtained using enzyme that had been cycled during purification. Enzyme was transferred in the Coy chamber to a cuvette and sealed before removal from the anaerobic environment. Anaerobic stock solutions of 2 M Me2S in ethanol and 2 M Me2SO in water were added to the cuvette using a gas-tight syringe.
Kinetic Analysis--
Kinetic constants for DMSOR, DMSOR-Y114A,
DMSOR-Y114F, TMAOR, and TMAOR+Y using Me2SO,
Me3NO, methionine sulfoxide (MetSO), and
adenosine-1N-oxide (ANO) as substrates were
determined as described previously (18). Three to ten activity assays
were performed for each of 5-10 different substrate concentrations.
Km and kcat values were
determined by direct fit to the Michaelis-Menten equation. Kinetic
constants for reduction of recombinant DMSOR, TMAOR, DMSOR-Y114A, DMSOR-Y114F, and TMAOR+Y using Me2S were determined using
the method of Adams et al. (17). Initial activity was
measured aerobically after the addition of Me2S from a
gas-tight syringe to a cuvette containing enzyme in the presence of 50 mM Tris, pH 8.0, 0.2 mM phenazine methosulfate
(PMS), and 0.04 mM 2,6-dichlorophenolindophenol (DCPIP).
Background activity, obtained by the addition of anaerobic Me2S to a cuvette containing no enzyme, was subtracted to
obtain all final activity numbers. All substrates were obtained from Sigma.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Creation of Expression Constructs-- Whereas E. coli TMAOR has previously been purified from source (30, 31) and a similar enzyme has been purified from S. massilia (32), the yield in both cases was substantially less than that obtained by the heterologous expression of R. sphaeroides DMSOR and BSOR in E. coli (3, 28). To facilitate purification of the large quantities of enzyme required for comprehensive studies on the role of the Tyr residue in DMSOR and TMAOR, E. coli TMAOR was cloned, homogeneously expressed, and purified. For overexpression, the gene for mature E. coli TMAOR with an added N-terminal His6 tag was placed into the pTrc 99 A vector.
Three mutants were created to elucidate the role of Tyr-114. In DMSOR, this residue was mutated to either Ala or Phe. The latter retains the large phenyl ring but cannot form a hydrogen bond to the molybdenum oxo ligand. The mutated sequences were transferred into a vector to generate His-tagged versions of DMSOR-Y114A and DMSOR-Y114F. In TMAOR, a Tyr codon was inserted into the His-tagged coding sequence between residues 119 and 120 in a position corresponding to Tyr-114 of DMSOR (Fig. 3A).
Expression Conditions-- BL21(DE3), the standard E. coli strain used for expression of pET plasmids, appears to have difficulty expressing enzymes containing the molybdenum cofactor (33). RK4353 is the base strain for an extensive series of cofactor biosynthesis mu insertion mutants (29), and it was chosen as an alternative expression strain. Since expression from pET-based plasmids requires the presence of T7 polymerase, the RK4353 strain was DE3-lysogenized. The plasmids expressing TMAOR reductase with and without a His tag (pKJ525 and pKJ725), DMSOR (pJH720), DMSOR-Y114A (pJN711), and DMSOR-Y114F (pJN712) were transformed into RK4353(DE3) cells. The resulting strains were subsequently transformed with pLysS.
Because of problems with cell stability as a result of DE3 lysogenization, an alternative expression system was created. Expression of R. sphaeroides DMSOR in the pTrc 99 A expression construct has been shown to produce a substantial improvement in yield and permits expression in an alternative cell strain without the presence of the T7 polymerase (28). The plasmids expressing His-tagged TMAOR, TMAOR+Y, and DMSOR in pTrc 99 A (pKJ825, pKJ830, and pJH820, respectively) were transformed into RK4353 E. coli cells.
All strains were grown and induced for 24 h under anaerobic conditions as described previously (3) with the exception that kanamycin and chloramphenicol were used as antibiotics for all RK4353(DE3) pLysS strains containing pET-based plasmids, and ampicillin was used for all expression from RK4353 cells containing pTrc 99 A-based plasmids. The IPTG concentration had to be lowered to 10 µM for expression of proteins from the pTrc 99 A vectors to obtain a level of active protein equivalent to that expressed from the pET vectors when induced with 40 µM IPTG.
Purification of TMAOR-- Analysis of DMSOR has shown that the presence of a N-terminal His6 tag does not alter the activity of the protein (18). To ascertain whether the same was true for TMAOR, both the native and His-tagged versions of the protein were expressed in RK4353(DE3) cells. After partial purification, the proteins exhibited similar kcat and Km values with Me3NO, indicating that the His tag does not interfere with catalytic competence. The elution profiles of both proteins on a GF-250 size exclusion high pressure liquid chromatography column were also similar, indicating equivalent folding and subunit composition. Therefore, tagged TMAOR was used for all further studies reported here.
TMAOR was purified to greater than 95% homogeneity after a 65 °C heat step was followed by Ni2+-NTA affinity and Q-Sepharose ion-exchange chromatography, as seen in Table II. Previous work with DMSOR has shown that purified, recombinant protein displays an altered absorption spectrum (18) and molybdenum coordination environment (11) compared with protein purified from source or recombinant protein after catalytic turnover. As shown in Fig. 4, absorption spectroscopy analysis indicates a similar phenomenon with TMAOR. The TMAOR Mo(VI) spectra obtained after purification without catalytic turnover is different from the Mo(VI) spectra obtained after one or more rounds of reduction and substrate oxidation. The uncycled TMAOR is unstable and shows rapid loss of activity at 4 °C associated with loss of the molybdenum atom. Activity assays with this species exhibit a distinct lag before a linear rate is observed. Upon addition of sodium dithionite, a reduced spectrum is obtained that is very similar to reduced BSOR and DMSOR (3). Once this enzyme is re-oxidized by addition of Me3NO, its spectrum shows molybdenum stretching bands in the longer wavelength region similar to those seen for DMSOR and BSOR (3). During further cycles of dithionite reduction and substrate oxidation, the enzyme cycles between the Mo(IV) and final Mo(VI) spectra and the original, as isolated, spectrum are not seen again.
|
|
Stability of activity was increased during purification by redox
cycling the crude lysate in an anaerobic chamber by the addition of
sodium dithionite in the presence of methyl viologen followed by
re-oxidation with Me3NO. Protein cycled during purification exhibits a Mo(VI) absorption spectrum similar to that seen for the
cycled enzyme, does not show a lag in activity, is stable for over a
week at 4 °C, and is stable indefinitely when stored at 20 °C.
Unless stated otherwise, the TMAOR and TMAOR+Y used in this paper were
redox-cycled during purification (Table II).
Pure TMAOR contains 1.94 mol of guanine per mol of protein, consistent with the presence of the bis(MGD)Mo cofactor found in both DMSOR (1, 2) and BSOR (3) and seen in the S. massilia TMAOR crystal structure (4). The specific activity for the recombinant TMAOR is comparable to or, in some cases, substantially better than that seen for the native enzyme grown anaerobically on Me3NO (30-32). Although the molybdenum content of the purified protein varied from 30 to 66%, the specific activity is constant at 1200 units/mg when normalized to 100% molybdenum. Expression using this system consistently produces 1.3 mg of active protein/liter of cell culture (0.3 mg of active protein/g cell), whereas purification of native enzyme has only provided, at best, 0.05 mg of protein/g of cells (32).
Purification and Molybdenum Incorporation of Mutants-- All mutant proteins were purified identically to their wild-type counterparts. Mutation of Tyr-114 in DMSOR, as well as the insertion of Tyr into TMAOR, does not affect the stability of the protein upon heating during purification, and the amount of protein produced per liter of cell culture is comparable to wild type (Table III). Incorporation of the molybdenum atom is also similar to that seen for the wild-type enzyme.
|
UV-visible Absorption Spectra--
All proteins are brownish green
after purification without redox cycling and exhibit Mo(VI) spectra
that are different from that seen for the cycled enzyme. The Mo(IV)
absorption spectra shown in Fig.
5A were determined by placing
the enzyme in an anaerobic environment and injecting sodium dithionite
directly into the cuvette until the spectra no longer changed and the
protein exhibited a light green color. The reduced Mo(IV) spectra
differ very little among all five species with the main absorption peak
exhibiting a max at about 640 nm. The Mo(VI) spectra
(Fig. 5B) were then obtained for TMAOR and TMAOR+Y by
addition of Me3NO until a stable brown protein was
obtained. The oxidized spectra of DMSOR, DMSOR-Y114A, and DMSOR-Y114F
were determined similarly using re-oxidation with Me2SO.
Comparison of the oxidized spectra shows larger variations than
observed among the reduced spectra. Whereas all of the main features
found in the DMSOR spectra at the longer wavelengths are still present
in TMAOR and the mutants, there are shifts in both the
max and the intensities of the peaks that indicate
subtle, yet distinct, perturbations in the molybdenum coordination
environments among the various proteins.
|
Kinetic Analysis-- The five purified proteins were analyzed by steady-state kinetics to determine the kcat and Km values for each with a variety of substrates (Table IV). Me2SO and MetSO are both S-oxides that are substrates for DMSOR (18, 21, 34). Me3NO and ANO are N-oxides that are substrates for both DMSOR and TMAOR (18, 21, 24, 32, 34, 35). All values were determined for purified enzyme and normalized to 100% molybdenum content. The mutations appear to alter the specificity for both S- and N-oxides. DMSOR-Y114F shows a significant decrease in the kcat/Km for both S-oxides and a small increase in the kcat/Km for Me3NO. Whereas DMSOR-Y114A shows a similar decrease in kcat/Km for Me2SO and MetSO to DMSOR-Y114F, there is a much larger increase in the kcat/Km for Me3NO. In TMAOR+Y, the kcat/Km for Me2SO increases slightly, and the kcat/Km for Me3NO decreases greatly.
|
Although the dominant effect of these mutations is on the Km, changes in the kcat values also influence the specificity. Both mutations in DMSOR show 2 orders of magnitude increases in the Km for Me2SO and MetSO relative to DMSOR. However, DMSOR-Y114F also shows a greater increase in the kcat values and, therefore, retains specificity constants closer to that of the wild-type enzyme. Similarly, this explains why little change is seen in the specificity constant for ANO. Whereas both mutations in DMSOR cause an order of magnitude increase in the kcat, this is matched by a similar order of magnitude increase in the Km, and the specificity constant changes no more than 2-fold.
Comparison of specificity constants (Table V) shows that DMSOR prefers the S-oxides, Me2SO and MetSO, to Me3NO by a factor of 210 and 5.3, respectively, and TMAOR prefers Me3NO to Me2SO and MetSO by a factor of 5,600 and 2,100, respectively. Mutation of Tyr-114 to a Phe in DMSOR significantly decreases the preference for Me2SO, and Me3NO is actually preferred to MetSO by a factor of 5. Mutation to an Ala changes the specificity more dramatically such that DMSOR-Y114A shows a greater preference for Me3NO than for either S-oxide. The opposite effect is seen upon the addition of a Tyr to TMAOR where there is a marked decrease in the preference for Me3NO. TMAOR+Y prefers Me3NO to Me2SO by a factor of 100 rather than the factor of 5,600 seen for the wild-type enzyme. TMAOR+Y also prefers Me3NO to MetSO by a factor of 150, an order of magnitude less than that seen for wild-type TMAOR.
|
Reduction with Me2S-- Whereas the ability of DMSOR to be reduced by Me2S has been studied extensively using various techniques (11, 15, 17), BSOR cannot be reduced by either Me2S or biotin (16), and the activity of TMAOR upon product addition has not been studied previously. To investigate how mutation of Tyr-114 alters this activity, data were obtained as described by Adams et. al. (17) using PMS and DCPIP as electron acceptors (Table VI). Attempts were also made to obtain the Me2S-reduced UV-visible absorption spectra with all seven enzymes (Fig. 6).
|
|
Although DMSOR purified from R. sphaeroides showed the
expected activity in the reverse assay, recombinant DMSOR, DMSOR-Y114F, and DMSOR-Y114A showed no activity unless they had first been cycled
and dialyzed before the assays were performed. The values for DMSOR
purified from R. sphaeroides and recycled, recombinant DMSOR
(6.5 and 8.2 s1, respectively) were
comparable to the previously published activity of R. capsulatus DMSOR of 8 s
1 (17). The
activity of wild-type TMAOR was 0.0035 s
1, 3 orders of magnitude less than for DMSOR. Both mutations in DMSOR showed
a shift in activity toward that seen for TMAOR. The activity of
DMSOR-Y114F (0.3 s
1) was an order of
magnitude less than DMSOR, whereas that for DMSOR-Y114A was 2 orders of
magnitude less (0.06 s
1). Significantly, the
introduction of a Tyr residue into TMAOR resulted in an increase in the
Vmax from 0.0035 to 0.13 s
1, to a level comparable to that of
DMSOR-Y114F. The Km values, however, were not very
different between TMAOR and TMAOR+Y, being 80 and 60 mM, respectively.
The Me2S-reduced spectra of both DMSOR purified from
R. sphaeroides (Fig. 6A) and the recombinant
protein after cycling (Fig. 6B) are very similar to that
published for the R. capsulatus enzyme (17). TMAOR shows
very little activity in the PMS/DCPIP assay upon addition of
Me2S or Me3N, and the Mo(VI) spectrum does not change with the addition of 200 mM Me2S or 200 mM Me3N. Although the reverse assay indicates
activity for DMSOR-Y114F, the absorption spectrum does not show any
significant reduction by Me2S (Fig. 6C).
Although the spectrum does change upon addition of 50 mM Me2S, this change does not appear to be caused by reduction
of the enzyme. There is no color change as seen in wild-type DMSOR, and
the decrease in absorbance in the 720 peak is not as large as seen in
the wild-type reduced enzyme, and the addition of Me2SO does not reverse the changes. DMSOR-Y114A (Fig. 6D) and
TMAOR+Y (Fig. 6E) also exhibit slight spectral changes upon
Me2S addition that do not appear to be caused by reduction
of the enzymes.
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Although the differences seen in the three different crystal structures of DMSOR have been recently resolved (5), the obvious flexibility of its active site still encourages comparison to similar enzymes. Whereas E. coli and S. massilia TMAOR have been purified previously from source, this is the first time that E. coli TMAOR has been cloned and overexpressed. Together with R. sphaeroides DMSOR and BSOR, this is the third member of the DMSOR family of molybdopterin enzymes to be cloned and purified at high levels in this laboratory. Overexpression consistently produces 1.3 mg of active protein/liter (0.3 mg of active protein/g cell), whereas purification of native enzyme has only provided, at best, 0.05 mg of protein/g cells (32). This provides a good system for mutagenic studies designed to investigate the mechanism of the DMSOR family and for detailed comprehensive studies using techniques such as EXAFS, resonance Raman, and EPR.
Mutation of the Tyr-114 in DMSOR and insertion of an equivalent Tyr
into TMAOR does not significantly alter the stability of the proteins
or interfere with cofactor or molybdenum binding. Molybdenum
incorporation is comparable to wild type, and none of the mutants
exhibit the heat instability exhibited by DMSOR lacking the complete
cofactor (28). UV-visible absorption spectra of oxidized and reduced
forms indicate that both DMSOR Tyr-114 mutations and TMAOR+Y turn over
in a manner similar to their respective wild-type proteins. Although
there are some shifts in the cycled Mo(VI) absorption spectra of the
mutants at longer wavelengths, all of the main features seen for the
wild-type proteins still remain, indicating that the molybdenum
coordination environments are similar. Resonance Raman studies have
indicated that the absorption peak at 550 nm is associated with the
MoO bond found in the hexa-coordinate, mono-oxo spectra (15, 16).
This absorption peak is changed very little from wild type in either of
the Tyr mutants, and it does not appear that the presence or absence of
this Tyr greatly perturbs the catalytic Mo
oxygen bond. The as
purified, oxidized spectra of all recombinant proteins differ from the
oxidized spectra obtained after reduction with dithionite and
re-oxidation with the appropriate substrate. Whereas the Mo(IV) and
cycled Mo(VI) spectra of TMAOR are very similar to the same spectra of
DMSOR and BSOR, the uncycled form of TMAOR exhibits several
characteristics that differ from as purified DMSOR. EXAFS analysis of
as purified, recombinant DMSOR indicates that, whereas all four
dithiolene sulfurs are ligated to the molybdenum, the serine ligand is
not bound until after the protein has been reduced with dithionite (11). Investigation of uncycled TMAOR by resonance Raman and EXAFS
should provide new information about another alternative active site conformation.
Although EXAFS, resonance Raman, and crystallography have supported the existence of a mono-oxo Mo(VI) to des-oxo Mo(IV) redox cycle (5, 10, 11, 15, 16), the flexibility of the DMSOR active site cannot be ignored. In addition to the two separate coordination environments seen in the recent DMSOR crystal structure, DMSOR and TMAOR both appear to adopt two different conformations prior to turnover. What role, if any, these alternative conformations play in the catalytic ability of this protein is still unclear.
Despite the high sequence similarity between DMSOR, TMAOR, and BSOR,
the substrate specificity varies markedly. Mutation of Tyr-114 to Phe
and Ala results in a decreased efficiency for reduction of
Me2SO and MetSO and an increased efficiency for reduction
of Me3NO. Whereas DMSOR-Y114F is not as good at reducing
S-oxides as DMSOR, the difference in the DMSOR-Y114A
mutation is more dramatic and more closely resembles TMAOR. Kinetic
analysis of TMAOR had already indicated that this enzyme does not
efficiently reduce S-oxides (24), and the data presented
here shows that insertion of a Tyr residue into this enzyme results in
an increased ability to reduce S-oxides relative to
Me3NO. Although the Y114 mutation in DMSOR was not
analyzed, in light of the comparison of TMAOR with and without a
residue at this position, it is assumed that deletion of this residue
in DMSOR would show the same shift to a preference for
N-oxides that was observed in the two Tyr-114 DMSOR mutants.
E. coli also contains a DMSOR that is able to use
Me3NO under physiological conditions. Although the
molybdenum-containing subunit of E. coli DMSOR shows
homology to Rhodobacter DMSOR and TMOAR, this enzyme also
contains an electron transfer subunit containing four [4Fe-4S]
clusters and a membrane anchor subunit (36). This enzyme is able to use
both Me3NO and Me2SO under physiologic
conditions and shows kinetic values similar to those of
Rhodobacter DMSOR, with
kcat/Km = 1.9 × 106 M1
s
1 for Me2SO (37) and
kcat/Km = 3.3 × 104 M
1
s
1 for Me3NO (21). Although,
Rhodobacter and E. coli DMSOR are able to
efficiently use Me3NO as a physiological substrate, they do
not catalyze the reaction as efficiently as TMAOR. The mutational analysis in this paper has shown that an increased efficiency in
reduction of Me3NO can be accompanied by a decreased
efficiency in Me2SO reduction and vice versa. This may
explain the need for a separate TMAOR in E. coli since it
allows maximization of the respiration efficiency with
Me3NO without compromising respiration on
Me2SO.
Significant differences are seen in the ability of these enzymes to proceed in the reverse direction. Although DMSOR is reducible by Me2S but not by Me3NO, previous work (16) with BSOR has shown that it cannot be reduced with Me2S, Me3N, or biotin. It has now been shown that TMAOR is not reduced upon the addition of either Me2S or Me3N. The as purified, recombinant DMSOR exists in a di-oxo, non-catalytically active form that does not have the serine ligand to the molybdenum (11). Although dithionite reduction is sufficient to attach the serine ligand and to convert the protein to the catalytically active form, Me2S is not strong enough to reduce the uncycled protein.
The presence of the Tyr residue near the cofactor appears to be essential but not sufficient for sustaining reduction by Me2S in this family of enzymes. The Vmax is reduced by an order of magnitude for DMSOR-Y114F and 2 orders of magnitude for DMSOR-Y114A when monitored using the Me2S/PMS/DCPIP assay. Insertion of a Tyr into TMAOR also increases the catalytic efficiency for reduction with Me2S but has no effect on the Km. Although a Me2S-reduced absorption spectrum can be obtained for R. sphaeroides DMSOR that is very similar to that already published for the R. capsulatus enzyme (17), addition of Me2S to DMSOR-Y114F and DMSOR-Y114A does not appear to result in the spectra of the reduced enzymes. Resonance Raman analysis of BSOR indicates that whereas the enzyme cannot be reduced by biotin or Me2S, both appear to bind to the oxidized enzyme and alter the resonance Raman spectra (16). Therefore, it is likely that the changes seen in the UV-visible spectra for DMSOR-Y114F, DMSOR-Y114A, and TMAOR+Y upon Me2S addition result from a Me2S-bound form of the oxidized enzyme. Although studying the Me2S-reduced form of DMSOR has provided valuable insight into the mechanism of this family, it does have limitations. It is unclear what physiological repercussions result from the loss of the Me2S oxidase activity, since neither BSOR nor TMAOR can be reduced by their substrates. The availability of the physiological electron donor for kinetic studies would be invaluable in answering these questions.
The manner in which Tyr-114 modulates the substrate specificity of this
class of enzymes cannot be answered without more complete mechanistic
studies. Although Tyr-114 has an effect upon substrate specificity,
this residue is clearly not sufficient on its own to modulate that
specificity. The most likely explanation to both of these questions
arises from the fact that this residue is close to the molybdenum atom
and may perturb the redox potential of the enzyme. Similar changes in
substrate specificity have been reported for E. coli TMAOR
and R. capsulatus DMSOR purified with a tungsten atom
replacing the molybdenum (25, 38) and for a mutation in R. sphaeroides DMSOR that changes the Ser ligand to the molybdenum to
a Cys (18). The tungsten derivative of TMAOR is reported to reduce
Me2SO, whereas the wild-type enzyme shows no
Me2SO reductase activity. Although this enzyme also appears to show a reduced activity for Me3NO, analytical metal
analysis was not reported for the purified protein, and there is no way of distinguishing whether incomplete tungsten incorporation causes the
lower activity with Me3NO. If one compares the
kcat/Km for Me2SO
to the kcat/Km for
Me3NO for tungsten-containing TMAOR, the value of 0.006 (25) is comparable to the number of 0.010 reported here for TMAOR+Y.
Although no data were presented for activity with Me3NO,
the tungsten derivative of R. capsulatus DMSOR has also
shown activity changes, including a loss in ability to be reduced by
Me2S (38). Additionally, the Ser-147 Cys mutation in
R. sphaeroides DMSOR results in a decreased specificity for
Me2SO and an increased specificity for ANO (18). In all three of these cases, the change in specificity is matched by a change
in redox potential. Detailed resonance Raman, EXAFS, EPR, and x-ray
crystallographic studies on the mutants generated in these studies
should provide greater understanding of how alterations in the vicinity
of the molybdenum atom affect the catalytic properties of the enzyme.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Ralph Wiley for assistance with growth and purification, Jason D. Nichols for site-directed mutagenesis of DMSOR, and Dr. Margot Wuebbens for critical review of this manuscript.
![]() |
FOOTNOTES |
---|
* This work was supported by Grant GM00091 from the National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 919-681-8845;
Fax: 919-684-8919; E-mail: raj@biochem.duke.edu.
Published, JBC Papers in Press, January 26, 2001, DOI 10.1074/jbc.M010965200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are:
DMSOR, dimethyl
sulfoxide reductase;
TMAOR, trimethylamine-N-oxide
reductase;
BSOR, biotin sulfoxide reductase;
bis(MGD)Mo, bis(molybdopterin guanine dinucleotide)molybdenum;
EXAFS, extended
X-ray absorption fine structure spectroscopy;
Me3NO, trimethylamine-N-oxide;
Me2SO, dimethyl
sulfoxide;
Me2S, dimethyl sulfide;
BSO, biotin sulfoxide;
IPTG, isopropyl--D-thiogalactopyranoside;
MetSO, methionine sulfoxide;
ANO, adenosine-1N-oxide;
PMS, phenazine methosulfate;
DCPIP, 2,6-dichlorophenolindophenol.
Unless otherwise noted, DMSOR refers to R. sphaeroides DMSOR
and TMAOR refers to E. coli TMAOR;
NTA, nitrilotriacetic
acid.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Hilton, J. C., and Rajagopalan, K. V. (1996) Arch. Biochem. Biophys. 325, 139-143[CrossRef][Medline] [Order article via Infotrieve] |
2. | Schindelin, H., Kisker, C., Hilton, J., Rajagopalan, K. V., and Rees, D. C. (1996) Science 272, 1615-1621[Abstract] |
3. | Temple, C. A., George, G. N., Hilton, J. C., George, M. J., Prince, R. C., Barber, M. J., and Rajagopalan, K. V. (2000) Biochemistry 39, 4046-4052[CrossRef][Medline] [Order article via Infotrieve] |
4. | Czjzek, M., Dos Santos, J.-P., Pommier, J., Giordano, G., Mejean, V., and Haser, R. (1998) J. Mol. Biol. 284, 435-447[CrossRef][Medline] [Order article via Infotrieve] |
5. | Hung-Kei, L., Temple, C. A., Rajagopalan, K. V., and Schindelin, H. (2000) J. Am. Chem. Soc. 122, 7673-7680[CrossRef] |
6. | McAlpine, A. S., McEwan, A. G., Shaw, A. L., and Bailey, S. (1997) J. Biol. Inorg. Chem. 2, 690-701[CrossRef] |
7. | McAlpine, A. S., McEwan, A. G., and Bailey, S. (1998) J. Mol. Biol. 275, 613-623[CrossRef][Medline] [Order article via Infotrieve] |
8. | Schneider, F., Löwe, J., Huber, R., Schindelin, H., Kisker, C., and Knäblein, J. (1996) J. Mol. Biol. 263, 53-69[CrossRef][Medline] [Order article via Infotrieve] |
9. | Baugh, P. E., Garner, C. D., Charnock, J. M., Collison, D., Davies, E. S., McAlpine, A. S., Bailey, S., Lane, I., Hanson, G. R., and McEwan, A. G. (1997) J. Biol. Inorg. Chem. 2, 634-643[CrossRef] |
10. | George, G. N., Hilton, J., and Rajagopalan, K. V. (1996) J. Am. Chem. Soc. 118, 1113-1117[CrossRef] |
11. | George, G. N., Hilton, J., Temple, C., Prince, R. C., and Rajagopalan, K. V. (1999) J. Am. Chem. Soc. 121, 1256-1266[CrossRef] |
12. |
Bastian, N. R.,
Kay, C. J.,
Barber, M. J.,
and Rajagopalan, K. V.
(1991)
J. Biol. Chem.
266,
45-51 |
13. | Bastian, N. R., Foster, M. J., and Pope, J. C. (1995) Biofactors 5, 5-10[Medline] [Order article via Infotrieve] |
14. | Bennett, B., Benson, N., McEwan, A. G., and Bray, R. C. (1994) Eur. J. Biochem. 225, 321-331[Abstract] |
15. | Garton, S. D., Hilton, J. C., Oku, H., Crouse, B. R., Rajagopalan, K. V., and Johnson, M. K. (1997) J. Am. Chem. Soc. 119, 12906-12916[CrossRef] |
16. |
Garton, S. D.,
Temple, C. A.,
Dhawan, I. K.,
Barber, M. J.,
Rajagopalan, K. V.,
and Johnson, M. K.
(2000)
J. Biol. Chem.
275,
6798-6805 |
17. | Adams, B., Smith, A. T., Bailey, S., McEwan, A. G., and Bray, R. C. (1999) Biochemistry 38, 8501-8511[CrossRef][Medline] [Order article via Infotrieve] |
18. |
Hilton, J. C.,
Temple, C. A.,
and Rajagopalan, K. V.
(1999)
J. Biol. Chem.
274,
8428-8436 |
19. |
Pollock, V. V.,
and Barber, M. J.
(2000)
J. Biol. Chem.
275,
35086-35090 |
20. | Silvestro, A., Pommier, J., Pascal, M. C., and Giordano, G. (1989) Biochim. Biophys. Acta 999, 208-216[Medline] [Order article via Infotrieve] |
21. | Satoh, T., and Kurihara, F. N. (1987) J. Biochem. (Tokyo) 102, 191-197[Abstract] |
22. | Pierson, D. E., and Campbell, A. (1990) J. Bacteriol. 172, 2194-2198[Medline] [Order article via Infotrieve] |
23. |
Pollock, V. V.,
and Barber, M. J.
(1997)
J. Biol. Chem.
272,
3355-3362 |
24. | Iobbi-Nivol, C., Pommier, J., Simala-Grant, J., Méjean, V., and Giordano, G. (1996) Biochim. Biophys. Acta 1294, 77-82[Medline] [Order article via Infotrieve] |
25. | Buc, J., Santini, C. L., Giordani, R., Czjek, M., Wu, L. F., and Giordano, G. (1999) Mol. Microbiol. 32, 159-168[Medline] [Order article via Infotrieve] |
26. | Hilton, J. C., and Rajagopalan, K. V. (1996) Biochim. Biophys. Acta 1294, 111-114[Medline] [Order article via Infotrieve] |
27. | Mejean, V., Iobbi-Nivol, C., Lepelletier, M., Giordano, G., Chippaux, M., and Pascal, M. C. (1994) Mol. Microbiol. 11, 1169-1179[Medline] [Order article via Infotrieve] |
28. |
Temple, C. A.,
and Rajagopalan, K. V.
(2000)
J. Biol. Chem.
275,
40202-40210 |
29. | Stewart, V., and MacGregor, C. H. (1982) J. Bacteriol. 151, 788-799[Medline] [Order article via Infotrieve] |
30. | Silvestro, A., Pommier, J., and Giordano, G. (1988) Biochim. Biophys. Acta 954, 1-13[Medline] [Order article via Infotrieve] |
31. | Yamamoto, I., Okubo, N., and Ishimoto, M. (1986) J. Biochem. (Tokyo) 99, 1773-1779[Abstract] |
32. | Dos Santos, J. P., Iobbi-Nivol, C., Couillault, C., Giordano, G., and Mejean, V. (1998) J. Mol. Biol. 284, 421-433[CrossRef][Medline] [Order article via Infotrieve] |
33. | Temple, C. A., Graf, T. N., and Rajagopalan, K. V. (2000) Arch. Biochem. Biophys. 383, 281-287[CrossRef][Medline] [Order article via Infotrieve] |
34. | Weiner, J. H., MacIsaac, D. P., Bishop, R. E., and Bilous, P. T. (1988) J. Bacteriol. 170, 1505-1510[Medline] [Order article via Infotrieve] |
35. | Shimokawa, O., and Ishimoto, M. (1979) J. Biochem. (Tokyo) 86, 1709-1717[Medline] [Order article via Infotrieve] |
36. | Weiner, J. H., Rothery, R. A., Sambasivarao, D., and Trieber, C. A. (1992) Biochim. Biophys. Acta 1102, 1-18[Medline] [Order article via Infotrieve] |
37. | Simala-Grant, J. H., and Weiner, J. H. (1998) Eur. J. Biochem. 251, 510-515[Abstract] |
38. | Stewart, L. J., Bailey, S., Bennett, B., Charnock, J. M., Garner, C. D., and McAlpine, A. S. (2000) J. Mol. Biol. 299, 593-600[CrossRef][Medline] [Order article via Infotrieve] |